NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Managing Director Shivakumar Pattabhiraman Completes Tenure at Indraprastha Medical Corp
Indraprastha Medical Corporation Limited announced that Mr. Shivakumar Pattabhiraman completed his 2-year tenure as Managing Director, effective close of business on November 4, 2026. He also ceased to be a member of the Stakeholders Relationship Committee as of the same date. The re-appointment had originally been approved at the AGM on September 24, 2024, for the period November 5, 2024 to November 4, 2026. A successor or interim leadership arrangement was not named in the disclosure.
உச்சம் நம்பிக்கை
என்ன மாறியதுMr. Shivakumar Pattabhiraman stepped down as Managing Director and Committee member upon completion of his scheduled 2-year term on November 4, 2026.
ஏன் இது முக்கியம்A transition at the top executive level is a key governance event for the Rs 3,080 Cr hospital operator, requiring clarity on future management succession and operational strategy.
📅 குறுகிய காலம்Neutral as the tenure completion was pre-scheduled, but market participants will watch for clarity on the appointment of the next Managing Director.
📈 நீண்ட காலம்Strategic direction and execution for high-margin elective procedures and bed occupancy will depend on the incoming leadership.
⚠ அபாய எச்சரிக்கைகள்
Leadership transition risk
Absence of immediate announcement regarding successor
👀 கவனிக்க வேண்டியவை
Monitor upcoming board meeting outcomes for announcements regarding the appointment of a new Managing Director or interim leadership to ensure operational continuity.
Indraprastha Medical Corporation Board Approves Q2 FY27 Unaudited Financial Results
Indraprastha Medical Corporation Limited held its Board of Directors meeting on October 29, 2026, approving the un-audited financial results for the quarter and half-year ended September 30, 2026. The meeting commenced at 3:00 PM and concluded at 4:15 PM alongside the receipt of the Limited Review Report from statutory auditors. Detailed financial figures were enclosed with the submission but not extracted in this cover document. Investors should review the complete financial annexure to gauge performance against its TTM revenue base of Rs 731 Cr.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுThe Board of Directors officially approved and released the Q2 and H1 FY27 financial results.
ஏன் இது முக்கியம்Provides critical financial insight into operating performance, patient volumes, and margin sustainability for a hospital operating with a TTM revenue of Rs 731 Cr.
Meeting commencement time: 3.00 p.m.Meeting conclusion time: 4.15 p.m.Financial period ended: 30th செப்டம்பர் 2026
📅 குறுகிய காலம்Market focus will shift immediately to revenue growth and EBITDA margins reported in the accompanying detailed tables.
📈 நீண்ட காலம்Limited from the cover letter itself; long-term value creation depends on occupancy efficiency, ALOS reduction, and ARPOB improvements.
⚠ அபாய எச்சரிக்கைகள்
Pricing controls on procedures
Geographic concentration in the NCR region
👀 கவனிக்க வேண்டியவை
Track the detailed profit and loss statement in the enclosed filing for metrics like Average Revenue Per Operating Bed (ARPOB), occupancy rates, and operating margins relative to prior periods.
Indraprastha Medical Fixes Sep 18, 2026 Record Date for Rs 4.00/Share Dividend
Indraprastha Medical Corporation Limited has scheduled its 38th Annual General Meeting (AGM) for September 24, 2026, and fixed September 18, 2026, as the record date for a dividend of Rs 4.00 per share (40% on face value of Rs 10) for FY 2025-26. The proposed payout represents an aggregate distribution of approximately Rs 36.6 crore, which is ~39.8% of the company's TTM net profit of Rs 92 crore. At the current market price of Rs 368.1, the dividend corresponds to a yield of roughly 1.1%. Subject to shareholder approval at the AGM, the dividend will be disbursed within 30 days of declaration.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company formally announced the AGM schedule, e-voting cut-off, and set the dividend record date to September 18, 2026.
ஏன் இது முக்கியம்Confirms capital return to shareholders with a payout of ~Rs 36.6 crore (~40% of TTM PAT), supported by low leverage (D/E of 0.05).
Proposed dividend per share: Rs 4.00 (40%)ரெக்கார்ட் தேதி: செப்டம்பர் 18, 2026AGM date: செப்டம்பர் 24, 2026Implied dividend yield: ~1.1%Estimated payout vs TTM PAT: ~39.8%
📅 குறுகிய காலம்The stock will trade cum-dividend until the trading session preceding the September 18, 2026 record date.
📈 நீண்ட காலம்Limited; routine annual dividend distribution reflecting steady cash generation and high ROCE (36.0%).
👀 கவனிக்க வேண்டியவை
Investors seeking to receive the dividend must hold shares before the ex-dividend date linked to the September 18, 2026 record date, and monitor the September 24 AGM for formal approval.
INDRAMEDCO Q1 PAT Up 8.5% YoY to ₹55.85 Cr; Revenue Grows 11.2%
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported a steady Q1 FY27 with revenue from operations rising 11.2% YoY to ₹406.15 cr. Net profit (PAT) grew by 8.5% YoY to ₹55.85 cr, while Profit Before Tax (PBT) saw a 9.5% increase to ₹74.82 cr. The company has fixed September 18, 2026, as the record date for the FY26 dividend and the upcoming Annual General Meeting. Operating margins faced slight pressure as professional charges to doctors rose 13.6% YoY, outpacing revenue growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its unaudited financial results for the first quarter of FY27 and announced the schedule for its Annual General Meeting and dividend record date.
ஏன் இது முக்கியம்The results demonstrate double-digit top-line growth, maintaining the company's 9-12% growth trajectory despite rising costs for medical professionals and materials.
Q1 Revenue from Operations: ₹406.15 கோடிQ1 Profit After Tax: ₹55.85 கோடிQ1 Revenue vs FY26 Annual Revenue: 27.4%Professional Charges to Doctors: ₹111.15 கோடிDividend Record Date: 18th செப்டம்பர், 2026
📅 குறுகிய காலம்The stock is likely to see neutral-to-positive sentiment following steady earnings growth and the confirmation of the dividend record date.
📈 நீண்ட காலம்The company continues to leverage the Apollo brand in the NCR region; long-term value depends on maintaining ARPOB growth and managing rising doctor professional fees.
⚠ அபாய எச்சரிக்கைகள்
Rising professional charges to doctors (up 13.6% YoY) exceeding revenue growth rate
Geographic concentration in the NCR region
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming AGM on September 24, 2026, for management commentary on bed occupancy rates and the impact of international patient volumes on margins.
ICRA Reaffirms [ICRA]AA (Stable) Rating for Indraprastha Medical Corp's Rs 162.50 Cr Facilities
ICRA Limited has reaffirmed the credit ratings for Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals), maintaining a strong investment-grade profile. The long-term rating for Rs 132.50 crore in facilities is reaffirmed at [ICRA]AA with a Stable outlook, while short-term facilities of Rs 30 crore are maintained at [ICRA]A1+. The total rated amount of Rs 162.50 crore includes a significant proposed term loan of Rs 92.50 crore. This reaffirmation underscores the company's continued financial stability and creditworthiness in the healthcare sector.
முக்கிய அம்சங்கள்
Long-term rating reaffirmed at [ICRA]AA (Stable) for Rs 132.50 crore in bank facilities.Short-term rating reaffirmed at [ICRA]A1+ for Rs 30.00 crore non-fund based limits.Total bank facilities rated by ICRA amount to Rs 162.50 crore.The rating includes a proposed term loan of Rs 92.50 crore for future capital requirements.Facilities are spread across major lenders including ICICI Bank, PNB, and HDFC Bank.
👀 கவனிக்க வேண்டியவை
Investors should view this reaffirmation as a confirmation of the company's robust financial health and low credit risk. No immediate portfolio changes are necessary as the credit profile remains stable and high-grade.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Indraprastha Medical Corp Recommends Final Dividend of Rs 4 Per Share
The Board of Directors of Indraprastha Medical Corporation Limited, at its meeting on May 12, 2026, has recommended a final dividend of Rs. 4 per equity share. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting. The company also clarified that it does not qualify as a 'Large Corporate' under SEBI's specific regulatory framework. The board meeting concluded at 4:35 p.m. following a session that began at 3:00 p.m.
முக்கிய அம்சங்கள்
Recommended a Final Dividend of Rs. 4 per equity share for the financial year.Board meeting held on May 12, 2026, concluded at 4:35 p.m.Confirmed non-applicability of 'Large Corporate' (LC) criteria per SEBI circulars.Dividend payout is subject to shareholder approval at the next AGM.
👀 கவனிக்க வேண்டியவை
Investors seeking regular income should monitor the upcoming record date to ensure eligibility for the Rs. 4 per share dividend. The stock remains a steady dividend-payer in the healthcare services sector.
Indraprastha Medical Corp Approves FY26 Results; Confirms Non-Large Corporate Status
Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals) has concluded its board meeting to approve financial results for the fiscal year ended March 31, 2026. The company officially declared that it does not meet the SEBI criteria for 'Large Corporate' (LC) status, which simplifies certain regulatory and borrowing disclosures. The board meeting was held on May 12, 2026, lasting approximately 95 minutes. This filing serves as the formal submission of the year-end financial performance to the stock exchanges.
முக்கிய அம்சங்கள்
Board meeting concluded on May 12, 2026, for the approval of financial results for the period ended March 31, 2026.Company confirmed it does not fulfill criteria for 'Large Corporate' status under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144.The board meeting commenced at 3:00 p.m. and concluded at 4:35 p.m.The submission includes Annexures A, B, and C representing the detailed financial statements and audit reports.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial annexures to evaluate the company's year-on-year growth and profitability margins. The non-LC status suggests the company's outstanding long-term borrowings are below the INR 100 crore threshold or it does not meet the market cap criteria.
Indraprastha Medical Approves Q3 Results; Appoints Harsh Pati Singhania to Board for 5-Year Term
Indraprastha Medical Corporation (Indraprastha Apollo) has approved its financial results for the quarter and nine months ended December 31, 2025. A significant update was provided regarding the ongoing land lease litigation for the Sarita Vihar hospital, with the Delhi Government filing a new affidavit in the Supreme Court. The company also announced major board changes, including the appointment of high-profile industrialist Harsh Pati Singhania as an Independent Director. Additionally, three existing independent directors were re-appointed for five-year terms, ensuring continuity in governance.
முக்கிய அம்சங்கள்
Approved un-audited financial results for the quarter and nine-month period ended December 31, 2025.Noted a new affidavit filed by the Delhi Government in the Supreme Court regarding the Sarita Vihar hospital land lease matter.Appointed Mr. Harsh Pati Singhania (CMD of JK Paper) as an Independent Director for a 5-year term until February 2031.Re-appointed three Independent Directors (Salil Singhal, Vineeta Rai, and Madhumita Ganguli) for second 5-year terms.The board meeting concluded on February 3, 2026, after a session lasting over two hours.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the Supreme Court proceedings regarding the land lease, as this remains a critical legal overhang for the company's primary asset. The addition of experienced industrial leadership to the board is a positive development for corporate governance.
Indraprastha Medical Appoints Harsh Pati Singhania to Board; Updates on Land Lease Legal Case
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) has approved its Q3 FY26 financial results and announced significant board changes. Mr. Harsh Pati Singhania, CMD of JK Paper, has been appointed as an Independent Director for a five-year term effective February 3, 2026. The company also re-appointed three other Independent Directors, including Mr. Salil Singhal and Ms. Madhumita Ganguli, for second five-year terms. Additionally, the company is reviewing a new affidavit filed by the Delhi Government in the Supreme Court regarding the ongoing land lease and free patient treatment matter.
முக்கிய அம்சங்கள்
Approved unaudited financial results for the quarter and nine months ended December 31, 2025Appointed Mr. Harsh Pati Singhania as Independent Director for a 5-year term ending February 2031Re-appointed three Independent Directors for 5-year terms to ensure board continuityNoted a new affidavit from the Govt. of NCT of Delhi regarding the Sarita Vihar hospital land lease litigationThe ongoing 'Free Patient Matter' remains under consideration by the Hon'ble Supreme Court of India
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the Supreme Court proceedings regarding the land lease and free patient matter as it represents a significant operational risk. The addition of high-profile industrial leaders to the board is a positive signal for corporate governance.
Indraprastha Medical Approves Q3 Results, Appoints Harsh Pati Singhania as Independent Director
Indraprastha Medical Corporation Limited (Indraprastha Apollo) has approved its Q3 FY26 financial results and announced several key board appointments. Mr. Harsh Pati Singhania, CMD of JK Paper, joins as an Independent Director, while three others, including Mr. Salil Singhal, have been re-appointed for five-year terms. The company is also monitoring a legal update involving an affidavit filed by the Delhi Government in the Supreme Court regarding land lease and free patient treatment. These developments highlight a focus on governance and ongoing regulatory challenges.
முக்கிய அம்சங்கள்
Approved un-audited financial results for the quarter and nine months ended December 31, 2025Appointed Mr. Harsh Pati Singhania (CMD, JK Paper) as Independent Director for a 5-year term starting Feb 2026Re-appointed three Independent Directors, including Mr. Salil Singhal, for 5-year termsNoted a new affidavit filed by the Delhi Government in the Supreme Court regarding the 'Free Patient Matter' and land lease
👀 கவனிக்க வேண்டியவை
Investors should review the detailed Q3 financial performance once published and closely monitor the Supreme Court proceedings regarding the land lease, as it represents a significant regulatory risk.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
